Date	e: <u>June/0</u>	1/2022	
		Yochihiro Laura	李翰美的
	nuscript Title: <u>The roles of adip</u> nuscript number (if known):		I-based therapy: Current Status and Future Scope- A narrative review
rela part to ti rela	ted to the content of your n ties whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" m affected by the content ecessarily indicate a bia t is preferable that you	all relationships/activities/interests listed below that are neans any relation with for-profit or not-for-profit third at of the manuscript. Disclosure represents a commitment as. If you are in doubt about whether to list a do so.  ships/activities/interests as they relate to the current
	nonowing questions apply t nuscript only.	o the author's relations	simps, activities, interests as they relate to the <u>current</u>
to the med	he epidemiology of hyperte dication, even if that medica	nsion, you should decla ation is not mentioned i aport for the work repor	be defined broadly. For example, if your manuscript pertain are all relationships with manufacturers of antihypertensive in the manuscript. rted in this manuscript without time limit. For all other iter
		Name all entities with	Specifications/Comments
, * · · ·		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
			nitial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame:	past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

				<u> </u>
5	Payment or honoraria for	None		
	lectures, presentations,			* A
	speakers bureaus,			
	manuscript writing or			
	educational events			
	Payment for expert	None		
	testimony			
	Support for attending	None		
.	meetings and/or travel			
	meetinge array or did to.			
	Patents planned, issued or	None		
	pending			
		1		
7	Participation on a Data	None		
	Safety Monitoring Board or			**************************************
	Advisory Board			
	Leadership or fiduciary role			
		/None		
	in other board, society,		· · · · · · · · · · · · · · · · · · ·	
	committee or advocacy			
	group, paid or unpaid			
	Stock or stock options	None		
-				
	<u> </u>			
ļ	Receipt of equipment,	None		
	materials, drugs, medical			
	writing, gifts or other	44,745,444		
	services			
	Other financial or non-	✓ None		
	financial interests			
1	·	<u> </u>		
ea	se summarize the above co	nflict of interest in the	following box:	
Tł	nere no conflict of interest to	declare regarding this	manuscript.	
			· · · · · · · · · · · · · · · · · · ·	
	is the state of th			
			•	20 °

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

	e: <u>May/3</u>	J/ ZUZZ	
Your	r Name:	Osaw Mazda	花田 山龙
Man	nuscript Title: The roles of adipo	ose-derived stem cells in cell-ba	ased therapy: Current Status and Future Scope- A narrative review
Man	uscript number (if known):		
relat parti to tr relat The man The to th med	ted to the content of your nies whose interests may be ransparency and does not notionship/activity/interest, it following questions apply truscript only.  author's relationships/activite epidemiology of hypertelication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationshit vities/interests should be nsion, you should declare tion is not mentioned in the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript perta all relationships with manufacturers of antihypertensi
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as	
		none (add rows as needed) Time frame: Since the initi	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	needed)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi	ial planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	needed) Time frame: Since the initi	ial planning of the work
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initiNone  Time frame: pa	ial planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	needed) Time frame: Since the initiNone  Time frame: pa	ial planning of the work
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	needed) Time frame: Since the initiNone  Time frame: pa	ial planning of the work

5	lectures, presentations, speakers bureaus,	None
	manuscript writing or educational events	
6	Payment for expert testimony	Noné
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None
Plea	se summarize the above co	nflict of interest in the following box:
Ti	nere no conflict of interest to	declare regarding this manuscript.
Dles	so place on "Y" pout to the	following statement to indicate your agreement.

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:	May/30/2022		
Your Name:	津下 到	Itaro Ts	juge
Manuscript Title: The	roles of adipose-derived stem co		: Current Status and Future Scope- A narrative review
Manuscript number	(if known):		
related to the conter parties whose intere to transparency and	it of your manuscript. "Rela sts may be affected by the	ated" means any rel content of the manu te a bias. If you are	nips/activities/interests listed below that are ation with for-profit or not-for-profit third uscript. Disclosure represents a commitment in doubt about whether to list a
The following question	ons apply to the author's re	elationships/activitie	es/interests as they relate to the <u>current</u>
to the epidemiology medication, even if t In item #1 below, rep	of hypertension, you shoul hat medication is not ment	d declare all relatior ioned in the manusc k reported in this ma	oadly. For example, if your manuscript pertairnships with manufacturers of antihypertensive cript.  anuscript without time limit. For all other iter
	Name all entitie	s with Specifica	tions/Comments
	whom you have relationship or in none (add rows needed)	this (e.g., if p ndicate institution	ayments were made to you or to your
	Time frame: Sinc	e the initial planning o	of the work
All support for the manuscript (e.g., 1 provision of study medical writing, a processing charge No time limit for the manuscript (e.g., 1).	materials, rticle s, etc.)		
2 Grants or contract		frame: past 36 months	5
any entity (if not i in item #1 above).	ndicated		
Royalties or licens		•	
4 Consulting fees	None		

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	None	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	✓ None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
·	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
		None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other	(	
4.2	services		
13	Other financial or non- financial interests	None	
	illianciai interests		
Dloa	se summarize the above co	nflist of interest in the falls	and a basis
rica	ise summarize the above co	muct of interest in the lond	owing box:
T	here no conflict of interest to	doclare regarding this man	ucoviet
''	nere no commet of interest to	deciare regarding this mar	iuscript.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	May/30/2022			
Your Name:	Daski	Inafuko	机场五水	
Manuscript Title: T	he roles of adipose-derived st	em cells in cell-based th	erapy: Current Status and Futu	re Scope- A narrative review
Manuscript numbe	r (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	✓ None	
ر		None	
	lectures, presentations,	,	
	speakers bureaus,		
	manuscript writing or		•
	educational events		
6	Payment for expert	None	
	testimony		
		·	
7	Support for attending	✓ None	
	meetings and/or travel		
2			
8	Patents planned, issued or	None	·
-	pending		
		·	4
9	Participation on a Data	✓ None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
11	Stock of Stock options	None None	
			,
12	Receipt of equipment,	None	
	materials, drugs, medical	-	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
875°			
Plea	se summarize the above co	nflict of interest in the foll	owing box:
.,,,,			
_	here no conflict of interest to	doclare regarding this man	aucarint
'	nere no cominci or interest to	deciare regarding this mai	iuscript.
L			
Plea	ase place an "X" next to the	following statement to inc	licate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

June/01/2022

Date:\_\_\_\_

You	r Name:	Tsionao - Kish	ida 7+19 fl D
Mar	nuscript Title: The roles of adipo		sed therapy: Current Status and Future Scope- A narrative review
Mar	nuscript number (if known):		
rela part to to rela The	ted to the content of your manies whose interests may be ransparency and does not not interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.  s/activities/interests as they relate to the current
to ti med In it	he epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.  In this manuscript without time limit. For all other items,
-		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
_	lectures, presentations,	None	
	speakers bureaus,	· · · · · · · · · · · · · · · · · · ·	
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel	Λ	
			· · · · · · · · · · · · · · · · · · ·
8	Patents planned, issued or	✓ None	
	pending		
	*		
9	Participation on a Data	✓ None	
	Safety Monitoring Board or	namen Laura de van	
	Advisory Board		
10	Leadership or fiduciary role	✓ None	
	in other board, society,	anno band an	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services	·	
13	Other financial or non-	None	
13	financial interests	None	
	Titlaticial interests		<del>anang panining kalandara kalandari kalandari kalandari kalandari kalandari kalandari kalandari kalandari kalandari</del>
		i i i i i i i i i i i i i i i i i i i	
Dlos	se summarize the above co	aflict of interact in the follo	wing hove
riec	ise summanze the above co	milet of interest in the folio	wing box.
_	hara no conflict of interest to	doclare regarding this man	usorint
,1	here no conflict of interest to	deciare regarding this man	uscript.
			,
	•		
			•
	nse place an "X" next to the		

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: <u>June/0</u>	1/2022		
		aoki	Morionoto	<u>我</u> 本尚我!
				ed therapy: Current Status and Future Scope- A narrative review
Mar	nuscript number (if known):			•
relat part to tr	ted to the content of your miles whose interests may be	nanuscrip affected ecessaril	ot. "Related" mear by the content of y indicate a bias. I	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to	o the aut	thor's relationship	s/activities/interests as they relate to the <u>current</u>
to ti		nsion, yo	ou should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is			in this manuscript without time limit. For all other iten
		Name a	II entities with	Specifications/Comments
		1	ou have this	(e.g., if payments were made to you or to your
		1 -	ship or indicate	institution)
			dd rows as	
Y 22 50		needed		l planning of the work
				i pranning of the work
1	All support for the present		Vone	
	manuscript (e.g., funding, provision of study materials,			
	medical writing, article		· · · · · · · · · · · · · · · · · · ·	
	processing charges, etc.)		•	. ,
	No time limit for this item.			
			Time frame: past	: 36 months
2	Grants or contracts from		_None	
	any entity (if not indicated			·
	in item #1 above).		-	
3	Royalties or licenses		_None	
4	Consulting fees		_None	

tures, presentations, eakers bureaus, nuscript writing or ucational events		
ACAMONAL EVENIS		
ment for expert	None	
oport for attending etings and/or travel	None	
ents planned, issued or ading	None	
ticipation on a Data ety Monitoring Board or visory Board	None	
dership or fiduciary role other board, society, omittee or advocacy up, paid or unpaid	None	
ck or stock options	None	
eipt of equipment, terials, drugs, medical ting, gifts or other vices	None	
er financial or non- ncial interests	None	
ımmarize the above co	nflict of interest in the following box:	
no conflict of interest to	declare regarding this manuscript.	
•		

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.